Aprea Therapeutics Files 8-K

Ticker: APRE · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1781983

Aprea Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyAprea Therapeutics, Inc. (APRE)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001, $22,800,000
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-reporting, operations

Related Tickers: APRE

TL;DR

APRE filed an 8-K on Jan 13, 2025. Details on financials and operations.

AI Summary

Aprea Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' within the provided text.

Why It Matters

This filing provides an update on Aprea Therapeutics' operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk.

Key Players & Entities

  • Aprea Therapeutics, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 3805 Old Easton Road (address) — Principal Executive Offices
  • Doylestown, PA (location) — Principal Executive Offices
  • 18902 (zip_code) — Principal Executive Offices
  • ( 617 ) 463-9385 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Aprea Therapeutics, Inc.'s results of operations and financial condition, as well as other events and financial statements.

When was this 8-K filed?

This 8-K was filed on January 13, 2025.

What is the principal executive office address for Aprea Therapeutics, Inc.?

The principal executive office address is 3805 Old Easton Road, Doylestown, PA 18902.

In which state was Aprea Therapeutics, Inc. incorporated?

Aprea Therapeutics, Inc. was incorporated in Delaware.

What is the telephone number listed for Aprea Therapeutics, Inc.?

The telephone number listed for Aprea Therapeutics, Inc. is (617) 463-9385.

Filing Stats: 652 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 08:00:39

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share APRE The Nasdaq Stock Mar
  • $22,800,000 — a cash and cash equivalents balance of $22,800,000. The foregoing financial information is

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Aprea Therapeutics, Inc. (the "Company") posted an updated corporate presentation slide deck (the "Corporate Presentation") to its website. In the Corporate Presentation, the Company disclosed that, as of December 31, 2024, it had a cash and cash equivalents balance of $22,800,000. The foregoing financial information is unaudited and preliminary, does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024, and remains subject to completion of the Company's financial statements for the fiscal year ended December 31, 2024. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference. The information included in Item 2.02 (including Exhibit 99.1) of this Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any Company filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. The Company disclosed that, as of December 31, 2024, it had a cash and cash equivalents balance of $22,800,000. The foregoing financial information is unaudited and preliminary, does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024, and remains subject to completion of the Company's financial statements for the fiscal year ended December 31, 2024.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Corporate Presentation (January 2025). 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aprea Therapeutics, Inc. Dated: January 13, 2025 By: /s/ Oren Gilad Name: Oren Gilad, Ph.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.